These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17240255)

  • 1. Preclinical safety of anecortave acetate.
    Heaton J; Kastner P; Hackett R
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S35-40. PubMed ID: 17240255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of the angiostatic cortisene anecortave acetate.
    Clark AF
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S26-34. PubMed ID: 17240253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posterior juxtascleral depot administration of anecortave acetate.
    Kaiser PK; Goldberg MF; Davis AA;
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S62-9. PubMed ID: 17240258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration.
    Augustin AJ; D'Amico DJ; Mieler WF; Schneebaum C; Beasley C
    Graefes Arch Clin Exp Ophthalmol; 2005 Jan; 243(1):9-12. PubMed ID: 15290154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical efficacy of anecortave acetate.
    Clark AF
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S41-8. PubMed ID: 17240256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and metabolism of anecortave acetate in animals and humans.
    Dahlin DC; Rahimy MH
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S49-61. PubMed ID: 17240257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posterior juxtascleral injection of anecortave acetate: magnetic resonance and echographic imaging and localization in rabbit eyes.
    Jockovich ME; Murray TG; Clifford PD; Moshfeghi AA
    Retina; 2007 Feb; 27(2):247-52. PubMed ID: 17290209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration.
    Regillo CD; D'Amico DJ; Mieler WF; Schneebaum C; Beasley CH; Sullins GT
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S70-8. PubMed ID: 17240259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation.
    Robin AL; Clark AF; Covert DW; Krueger S; Bergamini MV; Landry TA; Dickerson JE; Scheib SA; Realini T; Defaller JM; Cagle GD
    Am J Ophthalmol; 2009 Jan; 147(1):45-50.e2. PubMed ID: 18789793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes.
    Russell SR; Hudson HL; Jerdan JA;
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S79-90. PubMed ID: 17240260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First clinical experience with anecortave acetate (Retaane).
    Hayek S; Scherrer M; Barthelmes D; Fleischhauer JC; Kurz-Levin MM; Menghini M; Helbig H; Sutter FK
    Klin Monbl Augenheilkd; 2007 Apr; 224(4):279-81. PubMed ID: 17458792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anecortave acetate treatment for retinal angiomatous proliferation: a pilot study.
    Klais CM; Eandi CM; Ober MD; Sorenson JA; Sadeghi SN; Freund KB; Spaide RF; Slakter JS; Yannuzzi LA
    Retina; 2006 Sep; 26(7):773-9. PubMed ID: 16963850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study.
    Eandi CM; Ober MD; Freund KB; Klais CM; Slakter JS; Sorenson JA; Yannuzzi LA
    Retina; 2006 Sep; 26(7):780-5. PubMed ID: 16963851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypotensive effect of juxtascleral administration of anecortave acetate in different types of glaucoma.
    Prata TS; Tavares IM; Mello PA; Tamura C; Lima VC; Belfort R
    J Glaucoma; 2010 Sep; 19(7):488-92. PubMed ID: 20051887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amended final report on the safety assessment of polyacrylamide and acrylamide residues in cosmetics.
    Int J Toxicol; 2005; 24 Suppl 2():21-50. PubMed ID: 16154914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity.
    Penn JS; Rajaratnam VS; Collier RJ; Clark AF
    Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):283-90. PubMed ID: 11133880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Present status of studies on the treatment of choroidal neovascularization by Anecortave acetate].
    Li X; Wang YS
    Zhonghua Yan Ke Za Zhi; 2008 Jun; 44(6):571-4. PubMed ID: 19035252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anecortave (Alcon Laboratories).
    Vinores SA
    IDrugs; 2005 Apr; 8(4):327-34. PubMed ID: 15800808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice.
    Jockovich ME; Murray TG; Escalona-Benz E; Hernandez E; Feuer W
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1264-8. PubMed ID: 16565356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.